-
A plaintiff's evidence that a pain patch "malfunctioned" was sufficient to allow a jury to infer that it was defective for the purpose of imposing strict liability, the Illinois Appellate Court has ruled in affirming an $18 million jury verdict.
The plaintiff's wife died while using a Duragesic prescription transdermal patch to control chronic neck pain. The active ingredient in the patch is fentanyl, a strong narcotic painkiller.
-
Justin Lee Payne wasn't supposed to die in a motel room a hundred miles from home. The 23-year-old Evansville man was with friends on a trip out of town last May when their car broke down near the Kentucky-Tennessee border, and they were forced to spend the night in a motel.
The three began drinking to pass the time, and according to investigators at some point Payne pulled out a Duragesic skin patch he'd obtained illegally and offered to share it.
-
In the first federal pain patch trial, a Florida jury awarded $5.5 million to the father of a 28-year-old man who died at his computer while wearing a Duragesic patch.
It was the second victory in as many tries for the plaintiffs' bar, with a $772,000 win in Texas state court last summer.
-
..., Colliton noted Williams was using a "Duragesic patch" and "Avinza." (Id.) In her October 25, 2005...
-
WASHINGTON -- Federal regulators are investigating about 120 reported deaths that may be linked to overdoses from a pain relief patch that administers a potent narcotic through the skin, the Food and Drug Administration said Friday.
Johnson & Johnson's Duragesic patch can provide up to three days' relief from severe chronic pain, such as that experienced by bone cancer patients. But fentanyl, its active ingredient, is highly dangerous.
-
Mylan Laboratories Inc., the third-largest U.S. maker of generic drugs, said profit more than doubled, beating analysts' estimates, after demand surged for cheaper copies of a narcotic-laced pain patch. Net income for the quarter ended Sept. 30 rose to $77.5 million, or 36 cents a share, from $35.8 million, or 16 cents, a year earlier, Canonsburg-based Mylan said. Revenue jumped 21 percent to $357.8 million. Sales of Mylan's leading product, a copy of Johnson & Johnson's Duragesic pain patch, accounted for about 20 percent of revenue in the quarter after generating about 10 percent in fiscal 2006. Analysts have cautioned that Mylan's sales may decline once competitors begin selling other copies of the fentanyl- coated patch, which could occur at any time. "The company did OK, largely be...
-
Johnson & Johnson Inc. posted a 9 percent rise in second-quarter net income Tuesday and nudged up its profit forecast for the full year.
Sales of medical devices such as drug-coated stents, joint reconstruction and spine products lifted performance at the New Brunswick-based health care giant, countered by generic competition to its Duragesic pain patch.
-
Health care giant Johnson & Johnson was confronted yesterday with a $25 million lawsuit filed by the family of a Queen Anne's County woman, who drowned in her bathtub after using a pain medication patch the company has acknowledged may be defective.
The suit alleges that Patricia C. Wroten, 51, died on Feb. 6 as a result of a faulty Duragesic patch that leaked dangerous levels of opiates into her body.
-
By Bill Sizemore
The Virginian-Pilot
... delivered directly to the bloodstream via a patch placed on the skin. Among the other drugs given Fr... patch sold under the trade name Duragesic. Its website warns that the simultaneous use of th...
-
PITTSBURGH - Shares of Mylan Laboratories Inc. fell 7 percent Wednesday after the generic drug maker said it would sue the Food and Drug Administration to restore the agency's previous approval of a pain medication.
The FDA on Tuesday rescinded its approval for the introduction of Mylan's generic fentanyl transdermal patch, saying Janssen Pharmaceutica Products LP should maintain exclusive rights to sell its Duragesic patch for another six months.